Retinal Tissue Bioengineering, Materials and Methods for the Treatment of Glaucoma

Area of Science:

• Ophthalmology
• Regenerative Medicine
• Biotechnology

Background:

• Glaucoma is a leading cause of irreversible blindness due to retinal ganglion cell (RGC) degeneration.
• Current treatments for glaucoma only slow disease progression, with no cure for vision loss.
• RGC replacement therapies show potential for restoring vision and treating optic neuropathies.

Purpose of the Study:

• To review innovations in retinal regenerative medicine for glaucoma treatment.
• To focus on bio-engineering principles, biomaterials, and cell therapies for RGC replacement.
• To highlight advancements in overcoming challenges in RGC transplantation.

Main Methods:

• Review of current literature on retinal organoids and gene therapy for glaucoma.
• Focus on bio-engineering, biomaterials, and cell-based therapies.
• Exploration of strategies for cell sourcing, survival, and integration.

Main Results:

• Challenges in RGC replacement include identifying optimal cell sources, enhancing cell survival, and ensuring functional integration.
• Developing methods for immune-privileged cell delivery to the retina is crucial.
• Tissue-engineered scaffolds, retinal organoids, and gene therapy are key areas of development.

Conclusions:

• RGC replacement therapies hold significant potential for restoring visual function in glaucoma patients.
• Overcoming challenges in cell therapy requires advanced protocols and biotechnology.
• Tissue engineering and gene therapy are vital for developing clinically viable RGC treatments.